Joint (NASDAQ:JYNT) Posts Earnings Results, Beats Expectations By $0.02 EPS

Key Points

• EPS beat expectations: Joint reported quarterly earnings of $0.10 per share, $0.02 above the cited consensus, while revenue of $13.55 million fell short of analysts’ $14.85 million estimate.
• 2026 sales outlook was lowered: The company now expects system-wide sales of $508 million–$512 million and comparable sales to decline 3.5%–2.5%; adjusted EBITDA guidance was maintained at $12.5 million–$13.5 million.
• Profitability improved despite ongoing challenges: Third-quarter net income rose to $1.5 million from $290,000 a year earlier, but consumer-spending pressure and clinic closures remain concerns; shares fell 7.1% after the results.

Joint (NASDAQ:JYNT - Get Free Report) posted its earnings results on Thursday. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.02, Zacks reports. Joint had a net margin of 4.81% and a return on equity of 20.96%. The company had revenue of $13.55 million for the quarter, compared to analyst estimates of $14.85 million.

Here are the key takeaways from Joint's conference call:

• 2026 sales outlook was lowered: The Joint now expects system-wide sales of $508 million–$512 million and comps of negative 3.5% to negative 2.5%, citing continued pressure on consumer spending. Adjusted EBITDA guidance was maintained at $12.5 million–$13.5 million.
• Profitability from continuing operations improved: Third-quarter revenue rose 1% to $13.6 million, net income increased to $1.5 million from $290,000, and Adjusted EBITDA grew to $2.3 million from $1.4 million, reflecting the benefits of the capital-light franchisor model.
• Membership trends strengthened, but have not yet lifted comps: Active members per clinic, conversion, retention, and patient lifetime value improved, aided by flexible membership plans and lapsed-patient outreach. Lower monthly spending per patient—management estimated about $2 of dilution—offset some of those gains.
• Newer clinics are showing stronger economics: Management said recent 2026 openings have taken about three months on average to break even, versus roughly 18 months historically, attributing the improvement to stricter site selection, stronger operators, and pre-opening marketing requirements.
• Clinic closures and cash outflow remain considerations: The company expects year-end clinic count to be about 50 below 2025 as it closes underperforming locations, though it expects to resume clinic growth in 2027. Third-quarter operating cash flow was negative $128,000 and free cash flow was negative $509,000, including a $1.5 million legal-settlement payment.

Joint Stock Down 7.1%

JYNT traded down $0.52 during trading on Friday, hitting $6.85. 151,146 shares of the company traded hands, compared to its average volume of 49,725. Joint has a one year low of $6.63 and a one year high of $10.67. The stock's fifty day moving average is $7.66 and its 200 day moving average is $8.53. The firm has a market cap of $96.86 million, a P/E ratio of 29.78 and a beta of 1.16.

Key Joint News

Here are the key news stories impacting Joint this week:

• Positive Sentiment: JYNT reported third-quarter EPS of $0.10, up from $0.02 a year earlier and above the $0.08 consensus cited by MarketBeat. The company also expects 2026 system-wide sales of $508 million to $512 million. MarketBeat earnings report 2026 sales outlook
• Neutral Sentiment: Revenue was $13.55 million, up 1% year over year. The company is targeting a comparable-sales turnaround, but the available reports do not provide details on the timing or expected pace of recovery. Third-quarter results and franchise transition
• Negative Sentiment: Revenue fell short of the cited analyst expectation of $14.85 million. EPS estimates differed across sources: although the result beat MarketBeat’s $0.08 consensus, Zacks reported it missed its $0.11 estimate. The revenue shortfall and need to turn around comparable sales may temper investor confidence, particularly amid a challenging consumer environment. Zacks earnings estimates report

Wall Street Analyst Weigh In

Several brokerages have recently commented on JYNT. Weiss Ratings downgraded Joint from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday, October 26th. Wall Street Zen downgraded shares of Joint from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 16th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Joint currently has a consensus rating of "Reduce".

About Joint

The Joint Corp. NASDAQ: JYNT is a healthcare services company that operates The Joint Chiropractic, a network of chiropractic clinics in the United States. The company focuses on providing routine chiropractic care intended to support musculoskeletal health, mobility and general wellness.

The Joint Chiropractic clinics offer services such as chiropractic adjustments and related wellness care. The business model is designed to provide convenient, accessible care through walk-in visits, membership plans and prepaid packages, with an emphasis on transparent pricing and extended operating hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.